Bayer AG’s diacylglycerol kinase ζ (DGK-ζ) inhibitor BAY-2965501 is being developed as a first-in-class cancer immunotherapy candidate. The company recently presented preclinical data on the compound, which supported advancement of the candidate into clinical testing, with a first-in-human phase I study in solid tumors underway (NCT05614102).
Osteosarcoma (OS) is an aggressive cancer type, with frequent metastasis seen in the lungs, and for which two-thirds of metastatic patients fail to achieve durable responses and die due to the disease.
Researchers from Byondis BV and Sanquin Bloedvoorziening have published preclinical data on a new signal-regulatory protein α (SIRPα)-directed antibody, BYON-4228.
A new study has discovered a promising approach to improve the efficacy of adoptive cell therapies for cancer. The research, published in Molecular Therapy: Nucleic Acids, describes the development of novel Fas-TNFR chimeras acting as decoys for the Fas ligand and preventing it from binding to its natural receptor on the surface of chimeric antigen receptor (CAR) T cells.
Cancer immunotherapy candidate BSI-508, a bispecific fusion molecule targeting PD-1 and CD47, is undergoing early development at Biosion Inc., who recently presented preclinical data on the product.
IL-18 is a pro-inflammatory cytokine that triggers IFN-γ production and increases T- and NK-cell activity. IL-18’s effects are blocked by IL-18 binding protein (IL-18BP), an endogenous protein that binds to IL-18 with high affinity and that is highly present in the tumor microenvironment (TME).
Researchers from Bliss Biopharmaceutical Co. Ltd. presented the discovery and preclinical evaluation of BB-1701, a new HER2-targeting eribulin-containing antibody-drug conjugate (ADC) being developed as a potential new anticancer agent.
RSS
